readthroughSign in
Nov 16, 2026Weekly roundup

Ovarian cancer vaccine trial completes; new Phase 1 vaccine study registered for healthy volunteers

Two records update this week, one marking the completion of a Phase 2 ovarian cancer maintenance study and one registering a new early-stage prophylactic vaccine trial.

This week's updates span a completed Phase 2 oncology trial and a newly registered Phase 1 study.

  • The Phase 2 trial "TEDOVA" (NCT04713514), testing the vaccine OSE2101 (TEDOPI) alone or with pembrolizumab against best supportive care in platinum-sensitive recurrent ovarian cancer, is listed as completed with actual primary completion on 2025-12-15 and study completion on 2026-11-09. The trial randomized a total of 180 patients with HLA-A2 positive phenotype across three arms in a 1:1:2 ratio, with enrollment reaching 185 participants.1 The primary outcome is progression free survival, measured from randomization to progression or death.1
  • A new Phase 1 study of the investigational vaccine V951A (NCT07939399) was first posted on 2026-11-16 and is listed as not yet recruiting, with an estimated start date of 2026-11-30. The early study is testing an investigational vaccine called V951A in healthy volunteers, with goals including assessing safety, dose tolerability, and immune response.2 Enrollment is estimated at 252 participants.2

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.